The LifeSci Biotechnology Clinical Trials Index ("LSCIBC") is an equal weighted index that is designed to measure the equity market performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development. The inception date for LSCIBC was November 3, 2014.
